Skip to main content
OpenTrials
Completed

NCT Number: NCT02776748

PrEP in Breastfeeding Study

The purpose of this study is to quantify the magnitude and extent of infant exposure to daily emtricitabine (FTC) /tenofovir disoproxil fumarate (TDF) via maternal breastmilk when taken pre-exposure prophylaxis (PrEP) by lactating HIV-uninfected women. The primary outcome is the steady state concentrations of emtricitabine and tenofovir in the infant plasma.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HIV Pre-exposure Prophylaxis During Breastfeeding Behavior Breast Feeding Feeding Behavior

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Partners in Prevention-Thika, Thika, Kenya

Loading trial locations.

About this study

This is prospective, short-duration, open-label, single-arm, repeat-dose, pharmacokinetic study of daily FTC/TDF PrEP among HIV-uninfected lactating mother-infant pairs. PrEP will be administered to women through daily directly observed therapy for 10 consecutive days - sufficient to reach steady-state but discontinuing thereafter. No drug will be administered to the infant directly. Co-formulated FTC and TDF were dosed at 200 mg daily and 300 mg daily, respectively. The overall goal is to quantify the magnitude and degree to which breastfeeding infants are exposed to FTC/TDF when used as PrEP by HIV-uninfected lactating women. Maternal blood and breastmilk samples will be obtained concurrently (i.e., within 30 minutes of each other) regardless of the timing of food intake (i.e., non-fasting) on the 7th and 10th day. Peak samples will be obtained 1-2 hours after the maternal directly observed PrEP and trough samples were obtained at the end of the dosing interval (i.e., 23 to 24 hours after directly observed PrEP dose). A single infant blood sample will be obtained after the maternal 7th directly observed PrEP dose.

We will conduct quantitative measurements and analyses of infant plasma drug concentrations, infant-plasma to breastmilk and breastmilk to maternal plasma drug concentration ratios to characterize FTC and TDF transmission to breast feeding infants. Tenofovir and emtricitabine concentrations in plasma and breastmilk will be quantified via previously validated liquid chromatographic-tandem mass spectrometric (LC-MS/MS) methods in accordance with the recommendations included in the US Food and Drug Administration, Guidance for Industry, Bioanalytical Method Validation guidelines.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

For infant's mother and father

  • Able and willing to provide informed consent for the infant to participate in the study
  • Of legal age ≥18 years to consent

For HIV-uninfected mother, in addition to the criteria noted immediately above:

  • Willing to provide breast milk samples and breastfeed during the duration of the study 0-24 weeks postpartum
  • Breastfeeding an infant
  • HIV-uninfected based on negative HIV rapid tests, both at study screening and at the enrollment visit
  • Adequate renal function, defined by normal creatinine levels and estimated creatinine clearance ≥60 mL/min
  • Not infected with hepatitis B virus, as determined by a negative hepatitis B surface antigen test
  • Not currently using PrEP
  • Note: single mothers will be eligible to participate in this study. Where possible the father's permission was be obtained. When the father is unknown, incompetent, deceased, or not reasonably available, or when only the mother has the legal responsibility for the care and custody of the child, infant participation will be based on the mother's consent and documentation will be added to file.

For infant

  • Infant born to eligible women (both male and female infants will be included)
  • Age 0-24 weeks
  • Otherwise infant has no serious infections or active clinically significant medical problems

Exclusion criteria

  • Women breastfeeding more than one child
  • Preterm babies or infants with low birth weight (i.e. ≤2000mg)

Treatment and study plan

FTC/TDF PrEP

Drug

Daily oral directly observed FTC/TDF PrEP administered to breastfeeding HIV-uninfected women

Other names: Truvada PrEP

Primary outcomes

  1. Steady state plasma concentrations of emtricitabine and tenofovir in the infants of breastfeeding women using PrEP: Quantity of PrEP medications in the infant plasma.

    Time frame: Time averaged: 10 days

    Infant exposure measured as median (interquartile range) concentrations of emtricitabine and tenofovir infant plasma.

  2. Steady state plasma concentrations of emtricitabine and tenofovir in the infants of breastfeeding women using PrEP: Detectable and quantifiable concentrations of PrEP medications in the infant plasma.

    Time frame: Time averaged: 10 days

    Measure the proportion of infant plasma samples with concentrations of emtricitabine and tenofovir below the assay lower limit of quantification.

  3. Steady state concentrations of emtricitabine and tenofovir in plasma of HIV-uninfected women using PrEP.

    Time frame: Time averaged: 10 days

    Measure median (interquartile range) concentrations of emtricitabine and tenofovir in maternal plasma.

  4. Steady state concentrations of emtricitabine and tenofovir in breastmilk of HIV-uninfected women using PrEP.

    Time frame: Time averaged: 10 days

    Measure median (interquartile range) concentrations of emtricitabine and tenofovir in breast milk.

  5. Infant plasma-to-maternal breast milk emtricitabine and tenofovir concentration ratios.

    Time frame: Time averaged: 10 days

    Measure median (interquartile range) infant plasma-to-maternal breast milk emtricitabine and tenofovir concentration ratios.

  6. Infant daily dose of tenofovir and emtricitabine received from breastmilk

    Time frame: Time averaged: 10 days

    We will compute the infant drug dose received from breastmilk per day (infant Computed as the product of breast milk tenofovir and emtricitabine concentrations and the estimated volume of breast milk consumed by infant daily. We will assume the daily amount of breast milk consumed by the infant to be 150 mL/kg/day, the standardized milk consumption of the average milk intake of a fully breast-fed infant. Measure median (interquartile range) infant daily dose for tenofovir and emtricitabine from breastmilk.

  7. Infant dose fraction for tenofovir and emtricitabine.

    Time frame: Time averaged: 10 days

    Infant dose fraction (i.e., exposure index) represents the daily amount of drug dose an infant would ingest from breast milk as a percentage of the recommended pediatric therapeutic daily dose. Infant dose fraction will be computed as as: infant dose fraction (%) = infant dose from breast milk *100/infant therapeutic dose. Measure median (interquartile range) infant dose fraction.

  8. Maternal breastmilk emtricitabine and tenofovir to plasma concentration ratios.

    Time frame: Time averaged: 10 days

    Measure median (interquartile range) of maternal breastmilk emtricitabine and tenofovir to plasma concentration ratios.

  9. Serious adverse events in infants of breastfeeding HIV-uninfected women using PrEP.

    Time frame: Time averaged: 10 days

    Number of infants with serious adverse effects.

  10. Serious adverse events in breastfeeding HIV-uninfected women using PrEP.

    Time frame: Time averaged: 10 days

    Number of women with serious adverse effects.

Sponsors and collaborators

Lead sponsor

University of Washington

Other

Collaborators

  • Bill and Melinda Gates Foundation

Registry information

Official study title

An Open-label, Short-duration, Repeat-dose Study of Breastmilk Excretion and Infant Absorption of Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine When Used by HIV-uninfected Lactating Women

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
May 18, 2016
Registry last updated
Sep 21, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.